EMSITA D 50/5 TABLET is used to manage type II diabetes mellitus which is inadequately controlled on metformin monotherapy. It is a combination of Dapagliflozin and Sitagliptin which belongs to the group of medicines called Antidiabetic agents. It effectively controls blood sugar levels where dapagliflozin inhibits SGLT2, increasing urinary glucose excretion and reducing blood levels of glucose and Sitagliptin inhibits DPP-4, increases glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), resulting in increased insulin synthesis and decreased glucagon release.
No review given yet!
You need to Sign in to view this feature
This address will be removed from this list